Terms: = Liver cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
318 results:
1. Predicting effect of anti-pd-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and pd-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
3. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract] [Full Text] [Related]
4. Anti-pd-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
5. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
6. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.
Wang X; Niu R; Yang H; Lin Y; Hou H; Yang H
Cell Biol Int; 2024 May; 48(5):577-593. PubMed ID: 38501437
[TBL] [Abstract] [Full Text] [Related]
7. New advances in the study of pd-1/PD-L1 inhibitors-induced liver injury.
Yue M; Li C; Li G
Int Immunopharmacol; 2024 Apr; 131():111799. PubMed ID: 38460297
[TBL] [Abstract] [Full Text] [Related]
8. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.
Liang Y; Zhong D; Zhang Z; Su Y; Yan S; Lai C; Yao Y; Shi Y; Huang X; Shang J
BMC Cancer; 2024 Mar; 24(1):291. PubMed ID: 38438842
[TBL] [Abstract] [Full Text] [Related]
9. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-pd1 therapy.
Li ZC; Wang J; Liu HB; Zheng YM; Huang JH; Cai JB; Zhang L; Liu X; Du L; Yang XT; Chai XQ; Jiang YH; Ren ZG; Zhou J; Fan J; Yu DC; Sun HC; Huang C; Liu F
Cell Rep; 2024 Mar; 43(3):113877. PubMed ID: 38421869
[TBL] [Abstract] [Full Text] [Related]
10. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without pd-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
[TBL] [Abstract] [Full Text] [Related]
11. Interferon-α induces differentiation of cancer stem cells and immunosuppression in hepatocellular carcinoma by upregulating CXCL8 secretion.
Ma YT; Zheng L; Zhao CW; Zhang Y; Xu XW; Wang XY; Niu GP; Man ZS; Gu F; Chen YQ
Cytokine; 2024 May; 177():156555. PubMed ID: 38387232
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma.
Men B; Cui H; Han Z; Jin X; Xu Q; Jin Y; Piao Z; Zhang S
Front Immunol; 2024; 15():1337396. PubMed ID: 38380330
[TBL] [Abstract] [Full Text] [Related]
14. Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures.
Ahn B; Ahn HS; Shin J; Jun E; Koh EY; Ryu YM; Kim SY; Sung CO; Shim JH; Hong J; Kim K; Kang HJ
Liver Int; 2024 May; 44(5):1202-1218. PubMed ID: 38363048
[TBL] [Abstract] [Full Text] [Related]
15. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract] [Full Text] [Related]
16. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-pd-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
17. Tumor cell-derived LC3B
Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
[TBL] [Abstract] [Full Text] [Related]
18. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma.
Liu C; Zhou C; Xia W; Zhou Y; Qiu Y; Weng J; Zhou Q; Chen W; Wang YN; Lee HH; Wang SC; Kuang M; Yu D; Ren N; Hung MC
Nat Commun; 2024 Feb; 15(1):1009. PubMed ID: 38307859
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract] [Full Text] [Related]
20. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and pd-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
Ji J; Zhou C; Yan LL; Ma Y; Xu C; Wang FA; Zhou WZ; Lv PH
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):299-309. PubMed ID: 38291158
[TBL] [Abstract] [Full Text] [Related]
[Next]
